Article
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling.
Nature communications - 29 Oct 2020
Tripathi Rakshamani, Liu Zulong, Jain Aditi, Lyon Anastasia, Meeks Christina, Richards Dana, Liu Jinpeng, He Daheng, Wang Chi, Nespi Marika, Rymar Andrey, Wang Peng, Wilson Melissa, Plattner Rina
Abstract excerpt
Metastatic melanoma remains an incurable disease for many patients due to the limited success of targeted and immunotherapies. BRAF and MEK inhibitors reduce metastatic burden for patients with melanomas harboring BRAF mutations; however, most eventually relapse due to acquired resistance. Here, we demonstrate that ABL1/2 kinase activities and/or expression are potentiated in cell lines and patient samples...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.